GSK's Acquisition of Sirtris: Culture, Integration, and R&D Reform
This paper examines GlaxoSmithKline's (GSK) acquisition of Sirtris Pharmaceuticals, arguing that the deal was driven not simply by access to new drug compounds but by a desire to import Sirtris's entrepreneurial culture and innovative approach to drug discovery. The paper identifies the key advantages of the acquisition — particularly the potential to reform GSK's research and development processes — while also addressing significant drawbacks, including the risk of cultural erosion, human resources challenges, and the difficulty of integrating distinct drug discovery methodologies. Despite these tensions, the paper concludes that the acquisition ultimately added meaningful value to GSK's organization.
- Introduction: Strategic Rationale for the Acquisition: GSK sought Sirtris's entrepreneurial culture, not just drugs
- Advantages of Acquiring Sirtris: New energy injected into GSK's innovation and R&D
- Drawbacks and Integration Challenges: Cultural erosion, talent retention, and process integration risks
- Conclusion: Outcomes and Organizational Value: Acquisition ultimately added value to GSK
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper clearly articulates a dual thesis — that GSK sought to acquire a culture, not merely a product — and sustains that argument across both the advantages and drawbacks sections.
- It balances advocacy for the acquisition's benefits with an honest account of the risks, demonstrating analytical fairness.
- The use of a single, well-chosen case study source (Stuart & Weber, 2009) is applied precisely, with page-level citations that ground each claim.
Key academic technique demonstrated
The paper employs a cost-benefit analytical framework: it first establishes the strategic rationale, then enumerates concrete advantages, then honestly catalogs drawbacks, and finally delivers a verdict. This structure mirrors a professional business case analysis and is well suited to organizational strategy topics.
Structure breakdown
The paper moves in four logical steps: (1) framing the acquisition as a cultural purchase rather than a product purchase; (2) identifying the innovation-driven advantages; (3) examining three specific integration challenges — cultural preservation, talent retention, and process unification; and (4) resolving the tension with a concluding judgment that the reformed GSK discovery process proved effective. The argument is compact and tightly organized despite its brevity.
Introduction: Strategic Rationale for the Acquisition
When GlaxoSmithKline (GSK) acquired Sirtris, the purpose of the venture was not merely to purchase access to major new drugs that would prove lucrative additions to the portfolio, but to acquire a culture — a radically new model of business strategy, organization, and leadership. Contrary to the hierarchical GSK organizational structure and its traditional culture, Sirtris exhibited a more visionary, unique approach characterized by "entrepreneurial dynamism," exactly what fostered the firm's innovativeness (Stuart & Weber, 2009, p. 1). Sirtris offered a radically new approach to drug discovery that GSK recognized as adding value to the organization through a fundamental reform of its research and development processes.
Advantages of Acquiring Sirtris
The advantages of the acquisition were clear from the start: inject new energy into the innovative process through structural and methodological reforms. A "revolution" ensued, in which research, innovation, and development were combined with a performance-oriented culture (Stuart & Weber, 2009, p. 3).
Drawbacks and Integration Challenges
Of course, radical change was bound to present significant drawbacks for both GSK and Sirtris. A primary concern was how being absorbed by the industry giant would impact the actual culture of Sirtris, potentially undermining the very thing that initiated the acquisition in the first place. New communication styles and protocols needed to be implemented without disrupting Sirtris's organizational culture.
A second issue was related to human resources, both with regard to recruiting new talent and retaining existing staff. Scientists who would have been drawn to working for a radical innovator like Sirtris might not have been equally enamored by working for GSK. Integrating the drug discovery process into a common whole also proved to be a major challenge arising from the acquisition.
Conclusion: Outcomes and Organizational Value
However, the reformed GSK discovery process ultimately proved effective. The acquisition of Sirtris's unique approach to drug development helped reform the GSK processes of research and development to add significant value to the organization.
References
Stuart, T. & Weber, J. (2009). GSK's acquisition of Sirtris: Independence or integration?
You’re 94% through this paper. Sign up to read the full paper.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.